Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Microbot MedicalFRA:CY9D -3.82%36 3-Year RORE % is -36.26 as of Mar. 2026. GuruFocus rates FRA:CY9D with a GF Score™ of 36/100. The stock has 2 warning signs investors should review. Among 772 Medical Devices & Instruments companies, Microbot Medical ranks worse than 75.39% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Microbot Medical's 3-Year RORE % for the quarter that ended in Mar. 2026 was -36.26%.
The industry rank for Microbot Medical's 3-Year RORE % or its related term are showing as below:
FRA:CY9D's 3-Year RORE % is ranked worse than 75.39% of 772
companies
in the Medical Devices & Instruments industry
Industry Median: -4.05
vs FRA:CY9D: -36.26
Microbot Medical (FRA:CY9D) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Microbot Medical 3-Year RORE % Related Terms
Microbot Medical 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Microbot Medical's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:CY9D vs STXS, DXR, KRMD: 3-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, Microbot Medical's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Microbot Medical 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Microbot Medical's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Microbot Medical's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
Microbot Medical (FRA:CY9D) has a 3-Year RORE % of -36.26 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Microbot Medical and its competitors. According to the industry distribution chart, Microbot Medical ranks #582 out of 772 companies in the Medical Devices & Instruments industry, placing it in the top 75.4%.
Is Microbot Medical's 3-Year RORE % too high?
Microbot Medical's current 3-Year RORE % is -36.26. Based on the distribution chart, Microbot Medical ranks #582 out of 772 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Microbot Medical has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Microbot Medical's 3-Year RORE % compare to STXS and DXR?
According to the Medical Devices & Instruments industry distribution chart, Microbot Medical ranks #582 out of 772 companies for 3-Year RORE %. This places Microbot Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Microbot Medical and its competitors. Microbot Medical's current 3-Year RORE % is -36.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Microbot Medical stock overvalued right now?
Microbot Medical (FRA:CY9D) has a current 3-Year RORE % of -36.26. The current 3-Year RORE % is -36.26. Microbot Medical's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Microbot Medical (FRA:CY9D), the current 3-Year RORE % is -36.26 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Microbot Medical Inc is a medical device company specializing in the research, design, and development of next-generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, the company has developed the LIBERTY Endovascular Robotic Surgical System, a fully disposable robot for various endovascular interventional procedures. The company has a single operating and reportable segment, which is the development of robotic devices for endoluminal surgery.
36GF Score
Get the complete analysis for FRA:CY9D
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:CY9D has been successfully added to your 
